Min Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Min Liu has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Fan Yi
The Key Laboratory of Infection and Immunity of Shandong Province, Department of Pharmacology, School of Basic Medical Sciences, Shandong University, Jinan, China
10 shared publications Yu Sun
Department of Pharmacology, School of Basic Medical Sciences, Department of Clinical Laboratory, NHC Key Laboratory of Otorhinolaryngology, National Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, China
7 shared publicationsYan Zhang
Department of Pharmacology, School of Basic Medical Sciences, Department of Clinical Laboratory, NHC Key Laboratory of Otorhinolaryngology, National Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, China
6 shared publicationsJichao Wu
Department of Pharmacology, School of Basic Medical Sciences, Department of Clinical Laboratory, NHC Key Laboratory of Otorhinolaryngology, National Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, China
5 shared publicationsPing Zhan
Department of Pharmacology, School of Basic Medical Sciences, Shandong University, Jinan, China (M.L., X.L., P.Z., H.J., J.W., C.G., Z.W., X.W., W.T., F.Y.).
5 shared publications- Wei Tang
Department of Pathogenic Biology, School of Basic Medical Sciences, Shandong University, Jinan, China
5 shared publications
Latest Publications
- 6 November 2026
- Published by Springer Nature in Cell Death & Differentiation
- p. 1-14
DGKE acts as a negative regulator of podocyte migration and injury in glomerular diseases
- 6 November 2026
- Published by Springer Nature in Cell Death & Differentiation
- p. 1-14
DGKE acts as a negative regulator of podocyte migration and injury in glomerular diseases
- 1 June 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83  (6)
MYDGF Governs Endothelial Homeostasis in Hypertension
BACKGROUND: Endothelial dysfunction is recognized as a crucial initiating factor for hypertension and associated cardiovascular/renal injury. Although MYDGF (myeloid-derived growth factor) is mainly derived from bone marrow cells, recent studies have also found the expression of MYDGF in different parenchymal cells. However, the expression pattern and the role of endothelial MYDGF in hypertension remain unclear. METHODS: Endothelial-specific knockout of MYDGF mice and recombinant MYDGF were used to examine the role of MYDGF in hypertension and associated cardiovascular/renal injury. RESULTS: Endothelial MYDGF was significantly downregulated in hypertensive mice. MYDGF deficiency in the endothelium aggravated endothelial dysfunction and cardiovascular/renal injury in hypertensive mice, which was attenuated by the overexpression of MYDGF or recombinant MYDGF. Functionally, MYDGF maintained endothelial homeostasis via pleiotropic protective effects, including anti-inflammation, antiapoptosis, inhibiting aberrant endothelial permeability and senescence, and inducing NO generation. Mechanistically, MYDGF promoted the activation of HMOX1 (heme oxygenase-1) transcription by mediating STAT3 (signal transducer and activator of transcription 3) phosphorylation, thereby reestablishing endothelial homeostasis. CONCLUSIONS: MYDGF governs endothelial homeostasis in hypertension through regulating HMOX1 expression. Targeting MYDGF may offer an innovative approach for treating hypertension and its cardiovascular complications.
- 1 June 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83  (6)
MYDGF Governs Endothelial Homeostasis in Hypertension
BACKGROUND: Endothelial dysfunction is recognized as a crucial initiating factor for hypertension and associated cardiovascular/renal injury. Although MYDGF (myeloid-derived growth factor) is mainly derived from bone marrow cells, recent studies have also found the expression of MYDGF in different parenchymal cells. However, the expression pattern and the role of endothelial MYDGF in hypertension remain unclear. METHODS: Endothelial-specific knockout of MYDGF mice and recombinant MYDGF were used to examine the role of MYDGF in hypertension and associated cardiovascular/renal injury. RESULTS: Endothelial MYDGF was significantly downregulated in hypertensive mice. MYDGF deficiency in the endothelium aggravated endothelial dysfunction and cardiovascular/renal injury in hypertensive mice, which was attenuated by the overexpression of MYDGF or recombinant MYDGF. Functionally, MYDGF maintained endothelial homeostasis via pleiotropic protective effects, including anti-inflammation, antiapoptosis, inhibiting aberrant endothelial permeability and senescence, and inducing NO generation. Mechanistically, MYDGF promoted the activation of HMOX1 (heme oxygenase-1) transcription by mediating STAT3 (signal transducer and activator of transcription 3) phosphorylation, thereby reestablishing endothelial homeostasis. CONCLUSIONS: MYDGF governs endothelial homeostasis in hypertension through regulating HMOX1 expression. Targeting MYDGF may offer an innovative approach for treating hypertension and its cardiovascular complications.
- Open Access
- 23 March 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17  (1)
IFI16 is essential to linking DNA damage and ferroptosis in acute kidney injury
Emerging evidence demonstrates the important role of ferroptosis, a novel regulated cell death, in the initiation and progression of acute kidney injury (AKI). However, the activation mechanism of ferroptosis in AKI has not been fully revealed. The pivotal function of interferon inducible protein 16 (IFI16) in DNA damage response (DDR) as DNA sensor and regulator of cell death pathways encouraged us to examine its role in ferroptosis of renal tubular epithelial cells (TECs) in AKI. Here we report that the levels of IFI16 and its mouse ortholog p204 were elevated in the kidney of patients with acute tubular necrosis (ATN) and in TECs of mice with renal ischemia/reperfusion (I/R)-induced AKI (I/R-AKI). Under I/R conditions, tubule-specific p204 deficiency in mice and IFI16 knockout in HK-2 cells significantly ameliorated TEC ferroptosis. Mechanistically, IFI16 binds to poly(ADP-ribose) polymerase 1 (PARP-1) and enhances protein Poly ADP-ribosylation (PARylation), which in turn potentiates the ataxia-telangiectasia mutated (ATM)-p53 signaling contributing to lipid peroxidation and ferrous ion accumulation in TECs. In addition, IFI16-amplified DDR was dependent on its HIN and PYRIN domains. Thus, our findings provide a better understanding of a critical pathogenic axis linking DNA damage to ferroptosis and suggest that targeting IFI16 may be an innovative therapeutic strategy for treating patients with AKI.
- 23 March 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17  (1)
Open AccessIFI16 is essential to linking DNA damage and ferroptosis in acute kidney injury
Emerging evidence demonstrates the important role of ferroptosis, a novel regulated cell death, in the initiation and progression of acute kidney injury (AKI). However, the activation mechanism of ferroptosis in AKI has not been fully revealed. The pivotal function of interferon inducible protein 16 (IFI16) in DNA damage response (DDR) as DNA sensor and regulator of cell death pathways encouraged us to examine its role in ferroptosis of renal tubular epithelial cells (TECs) in AKI. Here we report that the levels of IFI16 and its mouse ortholog p204 were elevated in the kidney of patients with acute tubular necrosis (ATN) and in TECs of mice with renal ischemia/reperfusion (I/R)-induced AKI (I/R-AKI). Under I/R conditions, tubule-specific p204 deficiency in mice and IFI16 knockout in HK-2 cells significantly ameliorated TEC ferroptosis. Mechanistically, IFI16 binds to poly(ADP-ribose) polymerase 1 (PARP-1) and enhances protein Poly ADP-ribosylation (PARylation), which in turn potentiates the ataxia-telangiectasia mutated (ATM)-p53 signaling contributing to lipid peroxidation and ferrous ion accumulation in TECs. In addition, IFI16-amplified DDR was dependent on its HIN and PYRIN domains. Thus, our findings provide a better understanding of a critical pathogenic axis linking DNA damage to ferroptosis and suggest that targeting IFI16 may be an innovative therapeutic strategy for treating patients with AKI.
- Open Access
- 26 November 2024
- Published by Wiley in Advanced Science
- Vol. 12  (3) , e2409756
Tubular MYDGF Slows Progression of Chronic Kidney Disease by Maintaining Mitochondrial Homeostasis
Mitochondrial dysfunction is a key event driving the maladaptive repair of tubular epithelial cells during the transition from acute kidney injury to chronic kidney disease (CKD). Therefore, identifying potential targets involved in mitochondrial dysfunction in tubular epithelial cells is clinically important. Myeloidâderived growth factor (MYDGF), a novel secreted protein, plays important roles in multiple cardiovascular diseases, but the function of MYDGF in tubular epithelial cells remains unknown. In the present study, it is found that MYDGF expression is significantly reduced in the cortex of the kidney, especially in the proximal tubules, from mice with CKD. Notably, lower expression of MYDGF is observed in tubules from patients with CKD and the level of MYDGF correlated with key factors related to kidney fibrosis and estimated glomerular filtration rate (eGFR) in patients with CKD. Tubuleâspecific deletion of Mydgf exacerbates kidney injury in mice with CKD; however, Mydgf overexpression attenuates kidney fibrosis by remodeling mitochondrial homeostasis in tubular epithelial cells. Mechanistically, renal tubular MYDGF positively regulates the expression of isocitrate dehydrogenase 2 (IDH2), restores mitochondrial homeostasis, and slows CKD progression. Thus, this study indicates that MYDGF derived from tubules may be an effective therapeutic strategy for patients with CKD.
- 26 November 2024
- Published by Wiley in Advanced Science
- Vol. 12  (3) , e2409756
Open AccessTubular MYDGF Slows Progression of Chronic Kidney Disease by Maintaining Mitochondrial Homeostasis
Mitochondrial dysfunction is a key event driving the maladaptive repair of tubular epithelial cells during the transition from acute kidney injury to chronic kidney disease (CKD). Therefore, identifying potential targets involved in mitochondrial dysfunction in tubular epithelial cells is clinically important. Myeloidâderived growth factor (MYDGF), a novel secreted protein, plays important roles in multiple cardiovascular diseases, but the function of MYDGF in tubular epithelial cells remains unknown. In the present study, it is found that MYDGF expression is significantly reduced in the cortex of the kidney, especially in the proximal tubules, from mice with CKD. Notably, lower expression of MYDGF is observed in tubules from patients with CKD and the level of MYDGF correlated with key factors related to kidney fibrosis and estimated glomerular filtration rate (eGFR) in patients with CKD. Tubuleâspecific deletion of Mydgf exacerbates kidney injury in mice with CKD; however, Mydgf overexpression attenuates kidney fibrosis by remodeling mitochondrial homeostasis in tubular epithelial cells. Mechanistically, renal tubular MYDGF positively regulates the expression of isocitrate dehydrogenase 2 (IDH2), restores mitochondrial homeostasis, and slows CKD progression. Thus, this study indicates that MYDGF derived from tubules may be an effective therapeutic strategy for patients with CKD.
- 30 July 2024
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 35  (12) , 1655-1670
Lysosomal-Associated Protein Transmembrane 5, Tubular Senescence, and Progression of CKD
Key Points: Lysosomal-associated protein transmembrane 5 (LAPTM5) is increased in tubular epithelial cells in CKD. Conditional knockout of Laptm5 in tubules attenuates kidney fibrosis in mice with CKD. LAPTM5 contributes to tubular senescence by inhibiting WWP2-mediated ubiquitination of notch1 intracellular domain. Background: Tubular senescence is a major determinant of CKD, and identification of potential therapeutic targets involved in senescent tubular epithelial cells has clinical importance. Lysosomal-associated protein transmembrane 5 (LAPTM5) is a key molecule related to T- and B-cell receptor expression and inflammation. However, the expression pattern of LAPTM5 in the kidney and the contribution of LAPTM5 to the development of CKD are unknown. Methods: Laptm5 â/â mice and tubule specificâLaptm5 knockout mice were used to examine the role of LAPTM5 in tubular senescence by establishing different experimental mouse CKD models. Results: LAPTM5 expression was significantly induced in the kidney, especially in proximal tubules and distal convoluted tubules, from mice with aristolochic acid nephropathy, bilateral ischemia/reperfusion injuryâinduced CKD, or unilateral ureter obstruction. Tubule-specific deletion of Laptm5 inhibited senescence of tubular epithelial cells and alleviated tubulointerstitial fibrosis in aged mice. Moreover, Laptm5 deficiency ameliorated kidney injury and tubular senescence in mice with CKD. Mechanistically, LAPTM5 inhibited ubiquitination of notch1 intracellular domain by mediating WWP2 lysosomal degradation and then leading to cellular senescence in tubular epithelial cells. We also observed a higher expression of LAPTM5 in tubules from patients with CKD, and the level of LAPTM5 was correlated with kidney fibrosis and tubular senescence in people with CKD. Conclusions: LAPTM5 contributed to tubular senescence by regulating the WWP2/notch1 intracellular domain signaling pathway and exacerbated kidney injury during the progression of CKD.
- 30 July 2024
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 35  (12) , 1655-1670
Lysosomal-Associated Protein Transmembrane 5, Tubular Senescence, and Progression of CKD
Key Points: Lysosomal-associated protein transmembrane 5 (LAPTM5) is increased in tubular epithelial cells in CKD. Conditional knockout of Laptm5 in tubules attenuates kidney fibrosis in mice with CKD. LAPTM5 contributes to tubular senescence by inhibiting WWP2-mediated ubiquitination of notch1 intracellular domain. Background: Tubular senescence is a major determinant of CKD, and identification of potential therapeutic targets involved in senescent tubular epithelial cells has clinical importance. Lysosomal-associated protein transmembrane 5 (LAPTM5) is a key molecule related to T- and B-cell receptor expression and inflammation. However, the expression pattern of LAPTM5 in the kidney and the contribution of LAPTM5 to the development of CKD are unknown. Methods: Laptm5 â/â mice and tubule specificâLaptm5 knockout mice were used to examine the role of LAPTM5 in tubular senescence by establishing different experimental mouse CKD models. Results: LAPTM5 expression was significantly induced in the kidney, especially in proximal tubules and distal convoluted tubules, from mice with aristolochic acid nephropathy, bilateral ischemia/reperfusion injuryâinduced CKD, or unilateral ureter obstruction. Tubule-specific deletion of Laptm5 inhibited senescence of tubular epithelial cells and alleviated tubulointerstitial fibrosis in aged mice. Moreover, Laptm5 deficiency ameliorated kidney injury and tubular senescence in mice with CKD. Mechanistically, LAPTM5 inhibited ubiquitination of notch1 intracellular domain by mediating WWP2 lysosomal degradation and then leading to cellular senescence in tubular epithelial cells. We also observed a higher expression of LAPTM5 in tubules from patients with CKD, and the level of LAPTM5 was correlated with kidney fibrosis and tubular senescence in people with CKD. Conclusions: LAPTM5 contributed to tubular senescence by regulating the WWP2/notch1 intracellular domain signaling pathway and exacerbated kidney injury during the progression of CKD.
- 16 January 2024
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 45  (5) , 1019-1031
CCDC92 promotes podocyte injury by regulating PA28Îą/ABCA1/cholesterol efflux axis in type 2 diabetic mice
Podocyte lipotoxicity mediated by impaired cellular cholesterol efflux plays a crucial role in the development of diabetic kidney disease (DKD), and the identification of potential therapeutic targets that regulate podocyte cholesterol homeostasis has clinical significance. Coiled-coil domain containing 92 (CCDC92) is a novel molecule related to metabolic disorders and insulin resistance. However, whether the expression level of CCDC92 is changed in kidney parenchymal cells and the role of CCDC92 in podocytes remain unclear. In this study, we found that Ccdc92 was significantly induced in glomeruli from type 2 diabetic mice, especially in podocytes. Importantly, upregulation of Ccdc92 in glomeruli was positively correlated with an increased urine albumin-to-creatinine ratio (UACR) and podocyte loss. Functionally, podocyte-specific deletion of Ccdc92 attenuated proteinuria, glomerular expansion and podocyte injury in mice with DKD. We further demonstrated that Ccdc92 contributed to lipid accumulation by inhibiting cholesterol efflux, finally promoting podocyte injury. Mechanistically, Ccdc92 promoted the degradation of ABCA1 by regulating PA28Îą-mediated proteasome activity and then reduced cholesterol efflux. Thus, our studies indicate that Ccdc92 contributes to podocyte injury by regulating the PA28Îą/ABCA1/cholesterol efflux axis in DKD.
- 16 January 2024
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 45  (5) , 1019-1031
CCDC92 promotes podocyte injury by regulating PA28Îą/ABCA1/cholesterol efflux axis in type 2 diabetic mice
Podocyte lipotoxicity mediated by impaired cellular cholesterol efflux plays a crucial role in the development of diabetic kidney disease (DKD), and the identification of potential therapeutic targets that regulate podocyte cholesterol homeostasis has clinical significance. Coiled-coil domain containing 92 (CCDC92) is a novel molecule related to metabolic disorders and insulin resistance. However, whether the expression level of CCDC92 is changed in kidney parenchymal cells and the role of CCDC92 in podocytes remain unclear. In this study, we found that Ccdc92 was significantly induced in glomeruli from type 2 diabetic mice, especially in podocytes. Importantly, upregulation of Ccdc92 in glomeruli was positively correlated with an increased urine albumin-to-creatinine ratio (UACR) and podocyte loss. Functionally, podocyte-specific deletion of Ccdc92 attenuated proteinuria, glomerular expansion and podocyte injury in mice with DKD. We further demonstrated that Ccdc92 contributed to lipid accumulation by inhibiting cholesterol efflux, finally promoting podocyte injury. Mechanistically, Ccdc92 promoted the degradation of ABCA1 by regulating PA28Îą-mediated proteasome activity and then reduced cholesterol efflux. Thus, our studies indicate that Ccdc92 contributes to podocyte injury by regulating the PA28Îą/ABCA1/cholesterol efflux axis in DKD.
- Open Access
- 10 November 2023
- Published by Elsevier in Metabolism
- Vol. 150, 155724
CCDC92 deficiency ameliorates podocyte lipotoxicity in diabetic kidney disease
- 10 November 2023
- Published by Elsevier in Metabolism
- Vol. 150, 155724
Open AccessCCDC92 deficiency ameliorates podocyte lipotoxicity in diabetic kidney disease
- Top Cited PapersOpen Access
- 25 May 2023
- Published by Springer Nature in Nature Communications
- Vol. 14  (1) , 1-17
HDAC9-mediated epithelial cell cycle arrest in G2/M contributes to kidney fibrosis in male mice
Renal tubular epithelial cells (TECs) play a key role in kidney fibrosis by mediating cycle arrest at G2/M. However, the key HDAC isoforms and the underlying mechanism that are involved in G2/M arrest of TECs remain unclear. Here, we find that Hdac9 expression is significantly induced in the mouse fibrotic kidneys, especially in proximal tubules, induced by aristolochic acid nephropathy (AAN) or unilateral ureter obstruction (UUO). Tubule-specific deletion of HDAC9 or pharmacological inhibition by TMP195 attenuates epithelial cell cycle arrest in G2/M, then reduces production of profibrotic cytokine and alleviates tubulointerstitial fibrosis in male mice. In vitro, knockdown or inhibition of HDAC9 alleviates the loss of epithelial phenotype in TECs and attenuates fibroblasts activation through inhibiting epithelial cell cycle arrest in G2/M. Mechanistically, HDAC9 deacetylates STAT1 and promotes its reactivation, followed by inducing G2/M arrest of TECs, finally leading to tubulointerstitial fibrosis. Collectively, our studies indicate that HDAC9 may be an attractive therapeutic target for kidney fibrosis.
- 25 May 2023
- Published by Springer Nature in Nature Communications
- Vol. 14  (1) , 1-17
Top Cited PapersOpen AccessHDAC9-mediated epithelial cell cycle arrest in G2/M contributes to kidney fibrosis in male mice
Renal tubular epithelial cells (TECs) play a key role in kidney fibrosis by mediating cycle arrest at G2/M. However, the key HDAC isoforms and the underlying mechanism that are involved in G2/M arrest of TECs remain unclear. Here, we find that Hdac9 expression is significantly induced in the mouse fibrotic kidneys, especially in proximal tubules, induced by aristolochic acid nephropathy (AAN) or unilateral ureter obstruction (UUO). Tubule-specific deletion of HDAC9 or pharmacological inhibition by TMP195 attenuates epithelial cell cycle arrest in G2/M, then reduces production of profibrotic cytokine and alleviates tubulointerstitial fibrosis in male mice. In vitro, knockdown or inhibition of HDAC9 alleviates the loss of epithelial phenotype in TECs and attenuates fibroblasts activation through inhibiting epithelial cell cycle arrest in G2/M. Mechanistically, HDAC9 deacetylates STAT1 and promotes its reactivation, followed by inducing G2/M arrest of TECs, finally leading to tubulointerstitial fibrosis. Collectively, our studies indicate that HDAC9 may be an attractive therapeutic target for kidney fibrosis.
- Open Access
- 16 June 2022
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7  (14)
JAML promotes acute kidney injury mainly through a macrophage-dependent mechanism
Although macrophages are undoubtedly attractive therapeutic targets for acute kidney injury (AKI) because of their critical roles in renal inflammation and repair, the underlying mechanisms of macrophage phenotype switching and efferocytosis in the regulation of inflammatory responses during AKI are still largely unclear. The present study elucidated the role of junctional adhesion moleculeâlike protein (JAML) in the pathogenesis of AKI. We found that JAML was significantly upregulated in kidneys from 2 different murine AKI models including renal ischemia/reperfusion injury (IRI) and cisplatin-induced AKI. By generation of bone marrow chimeric mice, macrophage-specific and tubular cellâspecific Jaml conditional knockout mice, we demonstrated JAML promoted AKI mainly via a macrophage-dependent mechanism and found that JAML-mediated macrophage phenotype polarization and efferocytosis is one of the critical signal transduction pathways linking inflammatory responses to AKI. Mechanistically, the effects of JAML on the regulation of macrophages were, at least in part, associated with a macrophage-inducible C-type lectinâdependent mechanism. Collectively, our studies explore for the first time to our knowledge new biological functions of JAML in macrophages and conclude that JAML is an important mediator and biomarker of AKI. Pharmacological targeting of JAML-mediated signaling pathways at multiple levels may provide a novel therapeutic strategy for patients with AKI.
- 16 June 2022
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7  (14)
Open AccessJAML promotes acute kidney injury mainly through a macrophage-dependent mechanism
Although macrophages are undoubtedly attractive therapeutic targets for acute kidney injury (AKI) because of their critical roles in renal inflammation and repair, the underlying mechanisms of macrophage phenotype switching and efferocytosis in the regulation of inflammatory responses during AKI are still largely unclear. The present study elucidated the role of junctional adhesion moleculeâlike protein (JAML) in the pathogenesis of AKI. We found that JAML was significantly upregulated in kidneys from 2 different murine AKI models including renal ischemia/reperfusion injury (IRI) and cisplatin-induced AKI. By generation of bone marrow chimeric mice, macrophage-specific and tubular cellâspecific Jaml conditional knockout mice, we demonstrated JAML promoted AKI mainly via a macrophage-dependent mechanism and found that JAML-mediated macrophage phenotype polarization and efferocytosis is one of the critical signal transduction pathways linking inflammatory responses to AKI. Mechanistically, the effects of JAML on the regulation of macrophages were, at least in part, associated with a macrophage-inducible C-type lectinâdependent mechanism. Collectively, our studies explore for the first time to our knowledge new biological functions of JAML in macrophages and conclude that JAML is an important mediator and biomarker of AKI. Pharmacological targeting of JAML-mediated signaling pathways at multiple levels may provide a novel therapeutic strategy for patients with AKI.
- 25 May 2022
- Published by Elsevier in Kidney International
- Vol. 102  (3) , 546-559
Myeloid-derived growth factor deficiency exacerbates mitotic catastrophe of podocytes in glomerular disease
- 25 May 2022
- Published by Elsevier in Kidney International
- Vol. 102  (3) , 546-559
Myeloid-derived growth factor deficiency exacerbates mitotic catastrophe of podocytes in glomerular disease